Gain Therapeutics, Inc.’s GANX share price has surged by 13.74%, which has investors questioning if this is right time to sell.

and followed with two other licensing deals involving a pair of gene therapies for GM1 and GM2 gangliosidosis – AXO-AAV-GM1 and AXO-AAV-GM2 – from the University of Massachusetts. It also ...

Ophthalmology: ptosis (mitochondrial disorders, Menkes syndrome), retinal degeneration (grey matter disease), optic atrophy (white matter disease), cherry-red spots (GM1/2 gangliosidosis, Krabbe ...

After hours: March 21 at 4:46:09 PM EDT Loading Chart for GANX ...